for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Idorsia Ltd

IDIA.S

Latest Trade

27.04CHF

Change

0.10(+0.37%)

Volume

664,103

Today's Range

26.58

 - 

27.44

52 Week Range

18.44

 - 

33.43

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Latest Developments

Idorsia 9-month Net Loss Narrows To CHF 308 Million

Oct 27 (Reuters) - Idorsia Ltd <IDIA.S>::9M DILUTED EPS LOSS 2.25 CHF VERSUS 2.68 CHF LOSS YEAR AGO.US GAAP OPERATING EXPENSES 9M 2020 AT CHF 354 MILLION.NON-GAAP OPERATING EXPENSES 9M 2020 AT CHF 302 MILLION.UPDATED GUIDANCE FOR 2020: US GAAP OPERATING EXPENSES AROUND CHF 500 MILLION AND NON-GAAP OPERATING EXPENSES AROUND CHF 460 MILLION.US GAAP NET LOSS IN FIRST NINE MONTHS OF 2020 AMOUNTED TO CHF 308 MILLION COMPARED TO CHF 352 MILLION IN FIRST NINE MONTHS OF 2019.US GAAP REVENUE OF CHF 66 MILLION IN FIRST NINE MONTHS OF 2020.

Idorsia Completes Capital Increase With Gross Proceeds Of CHF 535.5 Mln

Oct 21 (Reuters) - IDORSIA LTD <IDIA.S>::IDORSIA SUCCESSFULLY COMPLETES CAPITAL INCREASE WITH GROSS PROCEEDS OF CHF 535.5 MILLION.WILL USE NET PROCEEDS OF ABOUT CHF 520 MILLION FROM CAPITAL INCREASE TO SUPPORT REGULATORY FILING AND, IF APPROVED, COMMERCIAL LAUNCH OF DARIDOREXANT AND TO FUND FURTHER DEVELOPMENT OF ITS DIVERSIFIED PIPELINE.EXPECTS TO RAISE GROSS PROCEEDS OF CHF 535.5 MILLION BASED ON OFFER PRICE OF CHF 22.50 PER NEW SHARE.

Idorsia Ltd ABB Bookrunner Says Books Will Close At 18.45PM UK

Oct 20 (Reuters) - Idorsia Ltd ABB Bookrunner Says :BLOCK TRADE: IDORSIA LTD ABB BOOKRUNNER SAYS BOOKS ARE COVERED; PRICE GUIDANCE TO FOLLOW.BLOCK TRADE: IDORSIA LTD ABB BOOKRUNNER SAYS ORDERS BELOW CHF22.50 RISK MISSING.BLOCK TRADE: IDORSIA LTD ABB BOOKRUNNER SAYS BOOKS ARE OVERSUBSCRIBED AT THAT LEVEL INCLUDING ORDER FROM CLOZEL FAMILY FOR C.2.75M SHARES.BLOCK TRADE: IDORSIA LTD ABB BOOKRUNNER SAYS BOOKS WILL CLOSE AT 18.45PM UK.

Idorsia Announces Results Of Its Rights Offering In Context Of Capital Increase

Oct 20 (Reuters) - IDORSIA LTD <IDIA.S>::IDORSIA ANNOUNCES THE RESULTS OF ITS RIGHTS OFFERING IN THE CONTEXT OF THE CAPITAL INCREASE.CAPITAL INCREASE BY WAY OF AN AT-MARKET RIGHTS OFFERING NOW MOVES TO BOOKBUILDING PROCESS FOR UP TO 7,974,681 SHARES.RIGHTS HAVE BEEN EXERCISED FOR 15,825,319 NEW SHARES, CORRESPONDING TO 66.5% OF MAXIMUM NUMBER OF UP TO 23,800,000 NEW SHARES OFFERED IN RIGHTS OFFERING.UP TO 7,974,681 SHARES NOT TAKEN UP BY EXISTING SHAREHOLDERS IN RIGHTS OFFERING ARE BEING OFFERED TO INVESTORS BY WAY OF A PUBLIC OFFERING IN SWITZERLAND.IDORSIA'S PRINCIPAL SHAREHOLDERS, JEAN-PAUL AND MARTINE CLOZEL, HAVE EXERCISED THEIR RIGHTS IN ORDER TO MAINTAIN CURRENT SHAREHOLDING OF 28.4% IN IDORSIA.THEY MAY ALSO PARTICIPATE IN INTERNATIONAL OFFERING AND POTENTIALLY INCREASE THEIR SHAREHOLDING UP TO 30%.CLOSE OF BOOKBUILDING PERIOD AS WELL AS OFFER PRICE ARE EXPECTED BEFORE OPENING OF SIX SWISS EXCHANGE ON OCTOBER 21, 2020.LISTING ACCORDING TO INTERNATIONAL REPORTING STANDARD OF SIX SWISS EXCHANGE, FIRST TRADING DAY, SETTLEMENT AND DELIVERY OF NEW SHARES IS EXPECTED TO BE ON OCTOBER 23.

Idorsia Announces Capital Increase

Oct 8 (Reuters) - Idorsia Ltd <IDIA.S>::IDORSIA ANNOUNCES CAPITAL INCREASE TO PREPARE FOR THE LAUNCH OF DARIDOREXANT AND FURTHER FUND ITS DIVERSIFIED PIPELINE.PROCEEDS FROM OFFERING WILL BE USED TO SUPPORT REGULATORY FILING AND, IF APPROVED, COMMERCIAL LAUNCH OF DARIDOREXANT AND TO FUND FURTHER DEVELOPMENT OF ITS DIVERSIFIED PIPELINE.IDORSIA ANNOUNCES CAPITAL INCREASE BY WAY OF AN AT-MARKET RIGHTS OFFERING WITH ENVISAGED GROSS PROCEEDS OF APPROXIMATELY CHF 575 MILLION.JEAN-PAUL AND MARTINE CLOZEL COMMITTED TO EXERCISE ALL THEIR SUBSCRIPTION RIGHTS IN ORDER TO MAINTAIN - AT LEAST - THEIR CURRENT SHAREHOLDING OF 28.4%.

Santhera Pharmaceuticals A Direct License Holder Of Vamorolone

Sept 2 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG <SANN.S>::EXERCISES OPTION TO OBTAIN WORLDWIDE RIGHTS TO VAMOROLONE IN DUCHENNE MUSCULAR DYSTROPHY AND ALL OTHER INDICATIONS.ANNOUNCES THAT IT HAS SIGNED AGREEMENTS WITH IDORSIA (SIX: IDIA) AND REVERAGEN BIOPHARMA INC., MAKING SANTHERA A DIRECT LICENSE HOLDER OF VAMOROLONE.EXPECTS A REDUCTION IN CASH OUTFLOW IN RANGE OF USD 18-24 MILLION IN NEXT 12-18 MONTHS.IN EXCHANGE FOR REVISED LICENSE RIGHTS, IDORSIA WILL RECEIVE 366,667 SANTHERA SHARES AND AN EXCHANGEABLE NOTE IN AMOUNT OF CHF 10 MILLION.REVERAGEN WILL RECEIVE USD 7 MILLION, IN MONTHLY INSTALMENTS OF UP TO USD 500,000, TO FUND ONGOING CLINICAL DEVELOPMENT OF VAMOROLONE.

Idorsia Selects Syneos Health As Commercialization Partner To Launch Daridorexant In US

Aug 31 (Reuters) - IDORSIA LTD <IDIA.S>::SELECTS SYNEOS HEALTH AS COMMERCIALIZATION PARTNER TO LAUNCH DARIDOREXANT IN UNITED STATES.

Idorsia H1 Non-GAAP Operating Expenses At CHF 193 Mln

July 23 (Reuters) - IDORSIA LTD <IDIA.S>::H1 NET LOSS -138 MILLION CHF.H1 DILUTED EPS LOSS 1.41 CHF VERSUS 1.77 CHF LOSS YEAR AGO.H1 US GAAP OPERATING EXPENSES 2020 AT CHF 236 MILLION.H1 NON-GAAP OPERATING EXPENSES AT CHF 193 MILLION.OUTLOOK 2020: US GAAP OPERATING EXPENSES AROUND CHF 530 MILLION AND NON-GAAP OPERATING EXPENSES AROUND CHF 490 MILLION.H1 US GAAP NET LOSS AMOUNTED TO CHF 189 MILLION COMPARED TO CHF 232 MILLION IN FIRST HALF OF 2019.

Cilag Holding Announces Proposed Offering Of Up To About 11.8 Mln Shares In Idorsia

July 8 (Reuters) - CILAG HOLDING::PROPOSED OFFERING OF UP TO APPROXIMATELY 11.8 MILLION EXISTING ORDINARY SHARES IN IDORSIA LTD.ON IDORSIA SHARE SALE, PRICE PER OFFER SHARE TO BE DETERMINED BY ACCELERATED BOOKBUILDING PROCESS TO INSTITUTIONAL INVESTORS.

Idorsia Completes Offering Of New Shares

May 20 (Reuters) - Idorsia Ltd <IDIA.S>::IDORSIA SUCCESSFULLY COMPLETES THE OFFERING OF NEW SHARES THEREBY SECURING FUNDING FOR THE COMPANY’S GROWTH PLAN.PLACED 11 MILLION NEW REGISTERED SHARES OF CHF 0.05 PAR VALUE EACH AT CHF 30 PER NEW SHARE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up